Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
Analytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisEureka AI Inside
Professional Services
Customer Stories
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
Trust and Security
PatentBench
LLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report How does tezepelumab's TSLP inhibition differ from IL-33 blockade (itepekimab, astegolimab) in phenotype coverage, clinical efficacy, and atopic march pipeline potential?
Article | Report APOE ε4 genotype ARIA risk multipliers and clinical decision framework for lecanemab and donanemab prescribing in Alzheimer's disease treatment.
Article | Report How do FXIa inhibitors asundexian and milvexian compare to apixaban and rivaroxaban on bleeding risk and efficacy? Patent and clinical trial evidence analysed.
Article | Report Head-to-head analysis of lecanemab, donanemab, and aducanumab across mechanism, Phase III efficacy, ARIA safety, dosing regimens, and clinical applicability.
Article | Report How do Tarlatamab and Elranatamab differ from gamma-delta T-cell therapies in TME penetration, cytokine release risk, and MHC-I resistance? A mechanistic analysis.
Article | Report How do patient population differences and I² heterogeneity (0%–95%) across five Lecanemab/Donanemab trials affect meta-analysis reliability and clinical applicability?
Article | Report A multi-dimensional safety analysis of lecanemab and donanemab ARIA risk data: RR 4.35 overall, APOE ε4 genotype stratification, and CNS superficial siderosis.
Article | Report How do FXR agonists, THRβ agonists, and ACC inhibitors differ in targeting MASH? Mechanistic analysis and pipeline combination strategy evidence.
Article | Report Meta-analysis comparing lecanemab and donanemab vs placebo across ADCOMS, CDR-SB, ADAS-Cog 14, and amyloid PET in early Alzheimer's disease. Full effect sizes, CIs, and heterogeneity data.
Article | Report DESTINY-Breast04's updated 32-month follow-up confirms T-DXd's OS and PFS benefit in HER2-low mBC, with key findings on ILD safety, ER-low subgroups, and ADC positioning.
Article | Report How voclosporin and sparsentan differ from cyclosporine in IgA nephropathy and FSGS — patent-disclosed structures, selectivity, and reduced nephrotoxicity explained.
Article | Report Analyse THRβ agonist selectivity SAR, hepatic uptake optimisation, ADME/PK profiles, and structural strategies that reduce cardiac and bone off-target effects vs non-selective THR agonists.
Article | Report DESTINY-Breast04 PFS2 data reveals T-DXd preserves sensitivity to subsequent therapies. Discover optimal T-DXd sequencing for HER2-low metastatic breast cancer.
Article | Report Analyse asundexian's oxopyridine scaffold, sub-nanomolar FXIa potency (Ki 0.26 nM), >38,000-fold selectivity over Factor Xa and thrombin, and structural differentiation from DOAC chemical series.
Article | Report DESTINY-Breast04 subgroup forest plot analysis: which HER2-low metastatic breast cancer patients derive the greatest OS benefit from T-DXd? Data-driven patient selection guide.